Reuters logo
BRIEF-Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
November 7, 2017 / 1:53 PM / 12 days ago

BRIEF-Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051

Nov 7 (Reuters) - Sarepta Therapeutics Inc:

* Sarepta Therapeutics announces FDA clearance of IND for the company’s ppmo exon 51 candidate, srp-5051

* Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below